血清钙蛋白颗粒大小及转化时间与动脉钙化、动脉僵硬及死亡率的关联
本研究为前瞻性队列研究,纳入402例新发血液透析患者(388例有T50数据),探讨血清二级钙蛋白颗粒(CPP2)大小及转化时间(T50)与基线动脉钙化、动脉僵硬及全因死亡的关系。结果显示CPP2大小和T50均与基线动脉钙化或僵硬无关联,但较大CPP2与死亡风险升高相关(HR 1.17,95%CI 1.05-1.31,每增加100nm),T50与死亡无关。
要点
- CPP2大小和T50与基线冠状动脉或胸主动脉钙化无关联。
- CPP2大小和T50与基线动脉僵硬(脉搏波传导速度、踝臂指数)无关联。
- 较大CPP2与全因死亡风险升高相关,T50与死亡无关联。
核心结论
- 在新发血液透析患者中,CPP2大小和T50均与 prevalent 动脉钙化和动脉僵硬无关。
- 较大CPP2与死亡风险升高相关(HR 1.17,95%CI 1.05-1.31,每增加100nm),但T50与死亡无关。
研究设计与样本
- 前瞻性队列研究,纳入PACE研究中新发血液透析患者,n=402有CPP2数据,n=388有T50数据。
主要发现
- 基线CPP2大小和T50与基线胎球蛋白A水平相关(r=-0.59和0.44,P<0.001)。
- 基线CPP2大小和T50与基线动脉钙化或动脉僵硬均无关联。
- 基线CPP2大小和T50与重复测量的脉搏波传导速度无关联。
- 中位随访3.5年(IQR 1.7-6.2),较大CPP2与死亡风险升高相关(HR 1.17,95%CI 1.05-1.31,每100nm),T50与死亡无关联。
临床怎么用
- CPP2大小和T50不宜作为新发血液透析患者动脉钙化或僵硬的生物标志物。
- 较大CPP2可能提示死亡风险升高,但需未来研究确认。
局限性
- 检测方法可能存在不精确性。
- 样本量较小。
- 结果推广至不同种族构成的新发HD人群受限。
- 存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Characteristics of the transformation of primary to secondary calciprotein particles (CPPs) in serum, including the size of secondary CPP (CPP2) aggregates and the time of transformation (T50), may be markers for arterial calcification in patients undergoing hemodialysis (HD). We examined the associations of CPP2 aggregate size and T50 with arterial calcification in incident HD patients. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Incident HD patients (n=402with available CPP2 measures and n=388with available T50 measures) from the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) Study PREDICTORS: Serum CPP2 size and T50 at baseline. OUTCOMES: Primary outcomes were baseline coronary artery and thoracic aorta calcifications. Exploratory outcomes included baseline arterial stiffness, measured by pulse wave velocity (PWV) and ankle brachial index, and longitudinally, repeat measures of PWV and all-cause mortality. ANALYTICAL APPROACH: Tobit regression, multiple linear regression, Poisson regression, linear mixed-effects regression, and Cox proportional hazards regression. RESULTS: Mean age was 55±13 years, 41% were women, 71% were Black, and 57% had diabetes mellitus. Baseline CPP2 size and T50 were correlated with baseline fetuin A level (r=-0.59 for CPP2 and 0.44 for T50; P<0.001 for both), but neither was associated with baseline measures of arterial calcification or arterial stiffness. Baseline CPP2 size and T50 were not associated with repeat measures of PWV. During a median follow-up of 3.5 (IQR, 1.7-6.2) years, larger CPP2 was associated with higher risk for mortality (HR, 1.17 [95% CI, 1.05-1.31] per 100nm larger CPP2 size) after adjusting for demographics and comorbid conditions, but there was no association between baseline T50 and risk for mortality. LIMITATIONS: Possible imprecision in assays, small sample size, limited generalizability to incident HD populations with different racial composition, and residual confounding. CONCLUSIONS: In incident HD patients, neither CPP2 size nor T50 was associated with prevalent arterial calcification and stiffness. Larger CPP2 was associated with risk for mortality, but this finding needs to be confirmed in future studies.
引用
- Chen W, Fitzpatrick J, Monroy-Trujillo JM, et al. Associations of Serum Calciprotein Particle Size and Transformation Time With Arterial Calcification, Arterial Stiffness, and Mortality in Incident Hemodialysis Patients. Am J Kidney Dis. 2020. PMID: 32800846. doi:10.1053/j.ajkd.2020.05.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。